Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Current Deferred Revenue (2018 - 2022)

Historic Current Deferred Revenue for Ani Pharmaceuticals (ANIP) over the last 8 years, with Q1 2022 value amounting to $116000.0.

  • Ani Pharmaceuticals' Current Deferred Revenue rose 1600.0% to $116000.0 in Q1 2022 from the same period last year, while for Mar 2022 it was $116000.0, marking a year-over-year increase of 1600.0%. This contributed to the annual value of $100000.0 for FY2021, which is 0.0% changed from last year.
  • Per Ani Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $116000.0 for Q1 2022, which was up 1600.0% from $100000.0 recorded in Q4 2021.
  • Ani Pharmaceuticals' 5-year Current Deferred Revenue high stood at $735000.0 for Q3 2018, and its period low was $100000.0 during Q4 2020.
  • For the 5-year period, Ani Pharmaceuticals' Current Deferred Revenue averaged around $319666.7, with its median value being $125000.0 (2020).
  • As far as peak fluctuations go, Ani Pharmaceuticals' Current Deferred Revenue plummeted by 8000.0% in 2020, and later skyrocketed by 1600.0% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $711000.0 in 2018, then decreased by 29.68% to $500000.0 in 2019, then plummeted by 80.0% to $100000.0 in 2020, then changed by 0.0% to $100000.0 in 2021, then increased by 16.0% to $116000.0 in 2022.
  • Its Current Deferred Revenue stands at $116000.0 for Q1 2022, versus $100000.0 for Q4 2021 and $100000.0 for Q3 2021.